Positive topline results from pooled safety analyses of roxadustat Phase 3 global program
Completed one year of treatment in Phase 2 trial evaluating pamrevlumab in treatment of non-ambulatory DMD patients
Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time
SAN FRANCISCO, May 09, 2019 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter of 2019 and provided an update on the company’s recent developments.
“The first quarter of 2019 saw critical execution across multiple programs. With respect to the global roxadustat anemia platform, we received positive topline results from analyses of pooled MACE and MACE+ da…
Source: Original Article